Variant · Amplification
NRAS Amplification
CI-VAR-00000236Explore in graph →CIViC 2550
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-26
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29245078
- Run
- ING-CIVIC-20260926-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Melanoma1 | ||||||||
| NRAS Amplification | (prognostic) | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID13301In a retrospective cohort of 657 patients with melanoma, 92 (14.0%) had NRAS copy-number gain (>2 copies). Patients with NRAS gain had shorter median overall survival than patients with normal NRAS co… (full text at CIViC) PMID 29245078 · Yan et al., 2018 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.